RBC Capital Reports That They Have Downgraded Enanta Pharmaceuticals (NASDAQ:ENTA) Shares

April 21, 2018 - By Vivian Currie

Investors sentiment decreased to 1.58 in Q4 2017. Its down 0.02, from 1.6 in 2017Q3. It worsened, as 12 investors sold Enanta Pharmaceuticals, Inc. shares while 36 reduced holdings. 29 funds opened positions while 47 raised stakes. 13.64 million shares or 12.66% more from 12.10 million shares in 2017Q3 were reported.

Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 549 shares in its portfolio. Moreover, Geode Cap Lc has 0% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 139,428 shares. Ubs Asset Mgmt Americas Inc reported 0% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). East Coast Asset Mngmt Ltd Liability reported 3,710 shares. Virginia Retirement Systems Et Al has 0.01% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Comerica State Bank has invested 0.01% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Alps invested 0.01% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Millennium Mgmt Ltd Liability Corporation owns 220,845 shares. Meeder Asset Management Incorporated has 0.01% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 1,124 shares. Oakworth holds 0% or 263 shares. Louisiana State Employees Retirement reported 0.02% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). 23,997 are owned by Arizona State Retirement Sys. 100 were reported by Grp One Trading L P. Vanguard Gp has 0% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 821,687 shares. Ajo Limited Partnership has 99,548 shares for 0.03% of their portfolio.

Since March 19, 2018, it had 0 insider buys, and 2 insider sales for $1.14 million activity. MELLETT PAUL J sold $778,331 worth of stock or 9,000 shares.

Enanta Pharmaceuticals (NASDAQ:ENTA) Receives a Downgrade

Market activity behind shares of Enanta Pharmaceuticals (NASDAQ:ENTA) will likely interesting today as RBC Capital downgraded the stock to a “Hold” rating.

Investors sentiment decreased to 1.58 in Q4 2017. Its down 0.02, from 1.6 in 2017Q3. It worsened, as 12 investors sold Enanta Pharmaceuticals, Inc. shares while 36 reduced holdings. 29 funds opened positions while 47 raised stakes. 13.64 million shares or 12.66% more from 12.10 million shares in 2017Q3 were reported.

Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 549 shares in its portfolio. Moreover, Geode Cap Lc has 0% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 139,428 shares. Ubs Asset Mgmt Americas Inc reported 0% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). East Coast Asset Mngmt Ltd Liability reported 3,710 shares. Virginia Retirement Systems Et Al has 0.01% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Comerica State Bank has invested 0.01% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Alps invested 0.01% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Millennium Mgmt Ltd Liability Corporation owns 220,845 shares. Meeder Asset Management Incorporated has 0.01% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 1,124 shares. Oakworth holds 0% or 263 shares. Louisiana State Employees Retirement reported 0.02% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). 23,997 are owned by Arizona State Retirement Sys. 100 were reported by Grp One Trading L P. Vanguard Gp has 0% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 821,687 shares. Ajo Limited Partnership has 99,548 shares for 0.03% of their portfolio.

Since March 19, 2018, it had 0 insider buys, and 2 insider sales for $1.14 million activity. MELLETT PAUL J sold $778,331 worth of stock or 9,000 shares.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Ratings Coverage

Among 4 analysts covering Enanta Pharmaceuticals (NASDAQ:ENTA), 0 have Buy rating, 0 Sell and 4 Hold. Therefore 0 are positive. Enanta Pharmaceuticals has $82.0 highest and $46.0 lowest target. $81’s average target is -7.42% below currents $87.49 stock price. Enanta Pharmaceuticals had 7 analyst reports since November 20, 2017 according to SRatingsIntel. The rating was downgraded by J.P. Morgan to “Hold” on Thursday, February 8. RBC Capital Markets maintained Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) rating on Wednesday, April 4. RBC Capital Markets has “Hold” rating and $8000 target. The firm earned “Hold” rating on Thursday, February 8 by Robert W. Baird. RBC Capital Markets downgraded the shares of ENTA in report on Tuesday, January 2 to “Sector Perform” rating. As per Thursday, February 8, the company rating was downgraded by JP Morgan. The stock of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has “Buy” rating given on Monday, November 20 by RBC Capital Markets. Robert W. Baird maintained the stock with “Hold” rating in Monday, November 20 report.

The stock increased 1.40% or $1.21 during the last trading session, reaching $87.49. About 93,424 shares traded. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has risen 160.80% since April 21, 2017 and is uptrending. It has outperformed by 149.25% the S&P500.

Analysts await Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to report earnings on May, 14. They expect $0.09 earnings per share, up 132.14 % or $0.37 from last year’s $-0.28 per share. ENTA’s profit will be $1.72M for 243.03 P/E if the $0.09 EPS becomes a reality. After $0.78 actual earnings per share reported by Enanta Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -88.46 % negative EPS growth.

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology firm focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company has market cap of $1.68 billion. The companyÂ’s research and development focuses on four disease targets: Hepatitis C virus , Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). It has a 49.97 P/E ratio. The Company’s lead product is paritaprevir, a protease inhibitor designed for use against HCV.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.